Drug safety profiles in geriatric patients with Parkinson's disease using the FORTA (Fit fOR The Aged) classification: results from a mono-centric retrospective analysis.
Drug safety
FORTA prescribing list
Geriatric patients
Multimorbidity
Parkinson’s disease
Polypharmacy
Journal
Journal of neural transmission (Vienna, Austria : 1996)
ISSN: 1435-1463
Titre abrégé: J Neural Transm (Vienna)
Pays: Austria
ID NLM: 9702341
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
10
08
2020
accepted:
05
11
2020
pubmed:
3
12
2020
medline:
16
10
2021
entrez:
2
12
2020
Statut:
ppublish
Résumé
To reduce potentially inappropriate medications, the FORTA (Fit fOR The Aged) concept classifies drugs in terms of their suitability for geriatric patients with different labels, namely A (indispensable), B (beneficial), C (questionable), and D (avoid). The aims of our study were to assess the medication appropriateness in PD inpatients applying the FORTA list and drug-drug interaction software, further to assess the adequacy of FORTA list for patients with PD. We retrospectively collected demographic data, comorbidities, laboratory values, and the medication from the discharge letters of 123 geriatric inpatients with PD at the university hospital of Hannover Medical School. Patients suffered on average from 8.2 comorbidities. The majority of the medication was labeled A (60.6% of PD-specific and 40.9% of other medication) or B (22.3% of PD-specific and 26.9% of other medication). Administered drugs labeled with D were amantadine, clozapine, oxazepam, lorazepam, amitriptyline, and clonidine. Overall, 545 interactions were identified, thereof 11.9% severe interactions, and 1.7% contraindicated combinations. 81.3% of patients had at least one moderate or severe interaction. The FORTA list gives rational recommendations for PD-specific and other medication, especially for general practitioners. Considering the demographic characteristics and the common multimorbidity of geriatric PD patients, this study underlines the importance of awareness, education, and preventive interventions to increase drug safety.
Identifiants
pubmed: 33263172
doi: 10.1007/s00702-020-02276-x
pii: 10.1007/s00702-020-02276-x
pmc: PMC7815558
doi:
Substances chimiques
Pharmaceutical Preparations
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
49-60Références
Anttila M, Sotaniemi E, Pelkonen O, Rautio A (2005) Marked effect of liver and kidney function on the pharmacokinetics of selegiline. Clin Pharmacol Ther 77:54–62. https://doi.org/10.1016/j.clpt.2004.09.004
doi: 10.1016/j.clpt.2004.09.004
pubmed: 15637531
Barker MJ, Greenwood KM, Jackson M, Crowe SF (2004) Persistence of cognitive effects after withdrawal from long-term benzodiazepine use: a meta-analysis. Arch Clin Neuropsychol 19:437–454. https://doi.org/10.1016/S0887-6177(03)00096-9
doi: 10.1016/S0887-6177(03)00096-9
pubmed: 15033227
Beers MH (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 151:1825. https://doi.org/10.1001/archinte.1991.00400090107019
doi: 10.1001/archinte.1991.00400090107019
pubmed: 1888249
Beers MH, Ouslander JG, Rollingher I et al (1991) Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med. https://doi.org/10.1001/archinte.1991.00400090107019
doi: 10.1001/archinte.1991.00400090107019
pubmed: 1888249
Beyer JL, Johnson KG (2018) Advances in pharmacotherapy of late-life depression. Curr Psychiatry Rep 20:34. https://doi.org/10.1007/s11920-018-0899-6
doi: 10.1007/s11920-018-0899-6
pubmed: 29627920
Borgohain R, Szasz J, Stanzione P et al (2014) Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson’s disease: long-term safinamide add-on in mid to late PD. Mov Disord 29:1273–1280. https://doi.org/10.1002/mds.25961
doi: 10.1002/mds.25961
pubmed: 25044402
Bose A, Li D, Gandhi C (2008) Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 16:14–20. https://doi.org/10.1097/JGP.0b013e3181591c09
doi: 10.1097/JGP.0b013e3181591c09
pubmed: 18165459
Budnitz DS, Lovegrove MC, Shehab N, Richards CL (2011) Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med. https://doi.org/10.1056/NEJMsa1103053
doi: 10.1056/NEJMsa1103053
pubmed: 22111719
Calderón-Larrañaga A, Vetrano DL, Onder G et al (2016) Assessing and measuring chronic multimorbidity in the older population: a proposal for its operationalization. GERONA. https://doi.org/10.1093/gerona/glw233
doi: 10.1093/gerona/glw233
Cawello W, Ahrweiler S, Sulowicz W et al (2012) Single dose pharmacokinetics of the transdermal rotigotine patch in patients with impaired renal function: rotigotine pharmacokinetics in renal impairment. Br J Clin Pharmacol 73:46–54. https://doi.org/10.1111/j.1365-2125.2011.04053.x
doi: 10.1111/j.1365-2125.2011.04053.x
pubmed: 21707699
pmcid: 3248255
Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40:373–383. https://doi.org/10.1016/0021-9681(87)90171-8
doi: 10.1016/0021-9681(87)90171-8
Chen T-Y, Winkelman JW, Mao W-C et al (2018) The use of benzodiazepine receptor agonists and the risk of hospitalization for pneumonia. Chest 153:161–171. https://doi.org/10.1016/j.chest.2017.07.030
doi: 10.1016/j.chest.2017.07.030
pubmed: 28782528
Chen JJ, Hua H, Massihi L et al (2019) Systematic literature review of quetiapine for the treatment of psychosis in patients with parkinsonism. JNP 31:188–195. https://doi.org/10.1176/appi.neuropsych.18080180
doi: 10.1176/appi.neuropsych.18080180
Csoti I, Herbst H, Urban P et al (2019) Polypharmacy in Parkinson’s disease: risks and benefits with little evidence. J Neural Transm (Vienna) 126:871–878. https://doi.org/10.1007/s00702-019-02026-8
doi: 10.1007/s00702-019-02026-8
Cummings J, Isaacson S, Mills R et al (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540. https://doi.org/10.1016/S0140-6736(13)62106-6
doi: 10.1016/S0140-6736(13)62106-6
pubmed: 24183563
de la Chapelle A, Kari C, Nurminen M, Hernberg S (1977) Clozapine-induced agranulocytosis: a genetic and epidemiologic study. Hum Genet 37:183–194. https://doi.org/10.1007/BF00393581
doi: 10.1007/BF00393581
pubmed: 885538
de Oliveira AM, Radanovic M, de Mello PCH et al (2015) Nonpharmacological interventions to reduce behavioral and psychological symptoms of dementia: a systematic review. Biomed Res Int 2015:218980. https://doi.org/10.1155/2015/218980
doi: 10.1155/2015/218980
pubmed: 26693477
pmcid: 4676992
Dechanont S, Maphanta S, Butthum B, Kongkaew C (2014) Hospital admissions/visits associated with drug-drug interactions: a systematic review and meta-analysis: HOSPITAL ADMISSIONS/VISITS ASSOCIATED WITH DDIs. Pharmacoepidemiol Drug Saf 23:489–497. https://doi.org/10.1002/pds.3592
doi: 10.1002/pds.3592
pubmed: 24616171
Deuschl G, Oertel W, Poewe W, Georg Thieme Verlag KG (2020) Parkinson-Syndrome und andere Bewegungsstörungen. Thieme Verlag KG. 2. überarbeitete Auflage. 978-3-13-241550-8 (ISBN)
Dewey RB Jr, Hutton JT, LeWitt PA, Factor SA (2001) A Randomized, double-blind, placebo-controlled trial of subcutaneously injected apomorphine for parkinsonian off-state events. Arch Neurol 58:1385. https://doi.org/10.1001/archneur.58.9.1385
doi: 10.1001/archneur.58.9.1385
pubmed: 11559309
Dias BM, dos Santos FS, Reis AMM (2019) Potential drug interactions in drug therapy prescribed for older adults at hospital discharge: cross-sectional study. Sao Paulo Med J 137:369–378. https://doi.org/10.1590/1516-3180.2019.013405072019
doi: 10.1590/1516-3180.2019.013405072019
pubmed: 31691770
El Morabet N, Uitvlugt EB, van den Bemt BJF, et al (2018) Prevalence and preventability of drug-related hospital readmissions: a systematic review. Journal of the American Geriatrics Society
Ernst FR, Grizzle AJ (2001) Drug-related morbidity and mortality: updating the cost-of-illness model. J Am Pharm Assoc (Washington, DC : 1996). https://doi.org/10.1016/S1086-5802(16)31229-3
doi: 10.1016/S1086-5802(16)31229-3
Factor SA, Friedman JH, Lannon MC et al (2001) Clozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12 week open label extension in the PSYCLOPS trial. Mov Disord 16:135–139. https://doi.org/10.1002/1531-8257(200101)16:1%3c135::aid-mds1006%3e3.0.co;2-q
doi: 10.1002/1531-8257(200101)16:1<135::aid-mds1006>3.0.co;2-q
pubmed: 11215574
Feldmann F, Zipprich HM, Witte OW (2020) Prell T (2020) Self-Reported Nonadherence Predicts Changes of Medication after Discharge from Hospital in People with Parkinson’s Disease. Parkinson’s Disease 44:1–8. https://doi.org/10.1155/2020/4315489
doi: 10.1155/2020/4315489
Ferreira JJ, Lees A, Rocha J-F et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165. https://doi.org/10.1016/S1474-4422(15)00336-1
doi: 10.1016/S1474-4422(15)00336-1
pubmed: 26725544
Fox SH, Katzenschlager R, Lim S-Y et al (2018) International Parkinson and movement disorder society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33:1248–1266. https://doi.org/10.1002/mds.27372
doi: 10.1002/mds.27372
pubmed: 29570866
Gallagher P, Ryan C, Byrne S et al (2008) STOPP (Screening Tool of Older Person’s Prescriptions) and START (Screening Tool to Alert doctors to Right Treatment). Consensus validation. Int J Clin Pharmacol Ther. https://doi.org/10.5414/CPP46072
doi: 10.5414/CPP46072
pubmed: 18218287
Gerbel S, Laser H, Schönfeld N, Rassmann T (2019) The Hannover Medical School Enterprise Clinical Research Data Warehouse: 5 Years of Experience. In Lecture Notes in Computer Science (including subseries Lecture Notes in Artificial Intelligence and Lecture Notes in Bioinformatics) LNBI 11371:182–194. https://doi.org/10.1007/978-3-030-06016-9_17
Glavin GB, Dugani AM, Pinsky C (1986) l-Deprenyl attenuates stress ulcer formation in rats. Neurosci Lett 70:379–381. https://doi.org/10.1016/0304-3940(86)90583-5
doi: 10.1016/0304-3940(86)90583-5
pubmed: 3095712
Guisado-Clavero M, Roso-Llorach A, López-Jimenez T, et al (2018) Multimorbidity patterns in the elderly: a prospective cohort study with cluster analysis. BMC Geriatr 18:16. https://doi.org/10.1186/s12877-018-0705-7
Hagell P, Odin P (2001) Apomorphine in the treatment of Parkinson’s disease. J Neurosci Nurs 33(21–34):37–38. https://doi.org/10.1097/01376517-200102000-00004
doi: 10.1097/01376517-200102000-00004
Hauser RA, Schapira AHV, Barone P et al (2014) Long-term safety and sustained efficacy of extended-release pramipexole in early and advanced Parkinson’s disease. Eur J Neurol 21:736–743. https://doi.org/10.1111/ene.12375
doi: 10.1111/ene.12375
pubmed: 24834511
pmcid: 4282380
Hauser RA, Silver D, Choudhry A et al (2014) Randomized, controlled trial of rasagiline as an add-on to dopamine agonists in Parkinson’s disease. Mov Disord 29:1028–1034. https://doi.org/10.1002/mds.25877
doi: 10.1002/mds.25877
pubmed: 24919813
Hill KD, Wee R (2012) Psychotropic drug-induced falls in older people: a review of interventions aimed at reducing the problem. Drugs Aging 29:15–30. https://doi.org/10.2165/11598420-000000000-00000
doi: 10.2165/11598420-000000000-00000
pubmed: 22191720
Hines LE, Murphy JE (2011) Potentially harmful drug-drug interactions in the elderly: a review. Am J Geriatr Pharmacother 9:364–377. https://doi.org/10.1016/j.amjopharm.2011.10.004
doi: 10.1016/j.amjopharm.2011.10.004
pubmed: 22078863
Hoehn MM, Yahr MD (1967) Parkinsonism: onset, progression and mortality. Neurology 17:427–442. https://doi.org/10.1212/wnl.17.5.427
doi: 10.1212/wnl.17.5.427
pubmed: 6067254
Holt S, Schmiedl S, Thürmann PA (2010) Potentially inappropriate medications in the elderly. Deutsches Aerzteblatt Online. https://doi.org/10.3238/arztebl.2010.0543
doi: 10.3238/arztebl.2010.0543
Hou JG, Wu LJ, Moore S et al (2012) Assessment of appropriate medication administration for hospitalized patients with Parkinson’s disease. Parkinsonism Relat Disord 18:377–381. https://doi.org/10.1016/j.parkreldis.2011.12.007
doi: 10.1016/j.parkreldis.2011.12.007
pubmed: 22236581
Hubble JP (2002) Long-term studies of dopamine agonists. Neurology 58:S42-50. https://doi.org/10.1212/wnl.58.suppl_1.s42
doi: 10.1212/wnl.58.suppl_1.s42
pubmed: 11909984
Johnell K, Klarin I (2007) The relationship between number of drugs and potential drug-drug interactions in the elderly: a study of over 600,000 elderly patients from the Swedish Prescribed Drug Register. Drug Saf 30:911–918. https://doi.org/10.2165/00002018-200730100-00009
doi: 10.2165/00002018-200730100-00009
pubmed: 17867728
Kadastik-Eerme L, Rosenthal M, Paju T et al (2015) Health-related quality of life in Parkinson’s disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes. https://doi.org/10.1186/s12955-015-0281-x
doi: 10.1186/s12955-015-0281-x
pubmed: 26088201
pmcid: 4474578
Klietz M, Tulke A, Müschen LH et al (2018) Impaired quality of life and need for palliative care in a German cohort of advanced Parkinson’s disease patients. Front Neurol 9:120. https://doi.org/10.3389/fneur.2018.00120
doi: 10.3389/fneur.2018.00120
pubmed: 29559949
pmcid: 5845640
Klietz M, Greten S, Wegner F, Höglinger GU (2019) Safety and tolerability of pharmacotherapies for Parkinson’s disease in geriatric patients. Drugs Aging 36:511–530. https://doi.org/10.1007/s40266-019-00654-z
doi: 10.1007/s40266-019-00654-z
pubmed: 30937878
Klietz M, Schnur T, Drexel S et al (2020) Association of motor and cognitive symptoms with health-related quality of life and caregiver burden in a German cohort of advanced Parkinson’s disease patients. Parkinson’s Dis 2020:5184084. https://doi.org/10.1155/2020/5184084
doi: 10.1155/2020/5184084
Krupp P, Barnes P (1989) Leponex ? associated granulocytopenia: a review of the situation. Psychopharmacology 99:S118–S121. https://doi.org/10.1007/BF00442575
doi: 10.1007/BF00442575
pubmed: 2682727
Lange R, Erbguth F (2017) Parkinson’s disease in the elderly. Z Gerontol Geriatr 50:547–559. https://doi.org/10.1007/s00391-017-1284-5
doi: 10.1007/s00391-017-1284-5
pubmed: 28725921
Leendertse AJ, Van Den Bemt PMLA, Bart Poolman J et al (2011) Preventable Hospital Admissions Related to Medication (HARM): cost analysis of the HARM study. Value Health. https://doi.org/10.1016/j.jval.2010.10.024
doi: 10.1016/j.jval.2010.10.024
pubmed: 21211484
Livingston G, Kelly L, Lewis-Holmes E et al (2014) A systematic review of the clinical effectiveness and cost-effectiveness of sensory, psychological and behavioural interventions for managing agitation in older adults with dementia. Health Technol Assess. https://doi.org/10.3310/hta18390
doi: 10.3310/hta18390
pubmed: 25300037
pmcid: 4781467
Luthringer R, Muzet M, Zisapel N, Staner L (2009) The effect of prolonged-release melatonin on sleep measures and psychomotor performance in elderly patients with insomnia. Int Clin Psychopharmacol 24:239–249. https://doi.org/10.1097/YIC.0b013e32832e9b08
doi: 10.1097/YIC.0b013e32832e9b08
pubmed: 19584739
Lyseng-Williamson KA (2012) Melatonin prolonged release: in the treatment of insomnia in patients aged ≥55 years. Drugs Aging 29:911–923. https://doi.org/10.1007/s40266-012-0018-z
doi: 10.1007/s40266-012-0018-z
pubmed: 23044640
Markota M, Rummans TA, Bostwick JM, Lapid MI (2016) Benzodiazepine use in older adults: dangers, management, and alternative therapies. Mayo Clin Proc 91:1632–1639. https://doi.org/10.1016/j.mayocp.2016.07.024
doi: 10.1016/j.mayocp.2016.07.024
pubmed: 27814838
McLean G, Hindle JV, Guthrie B, Mercer SW (2017) Co-morbidity and polypharmacy in Parkinson’s disease: insights from a large Scottish primary care database. BMC Neurol 17:126. https://doi.org/10.1186/s12883-017-0904-4
doi: 10.1186/s12883-017-0904-4
pubmed: 28666413
pmcid: 5493890
Meltzer HY, Mills R, Revell S et al (2010) Pimavanserin, a serotonin(2A) receptor inverse agonist, for the treatment of Parkinson’s disease psychosis. Neuropsychopharmacology 35:881–892. https://doi.org/10.1038/npp.2009.176
doi: 10.1038/npp.2009.176
pubmed: 19907417
Mizuno Y, Nomoto M, Kondo T et al (2013) Transdermal rotigotine in early stage Parkinson’s disease: a randomized, double-blind, placebo-controlled trial: rotigotine in early-stage Parkinson’s disease. Mov Disord 28:1447–1450. https://doi.org/10.1002/mds.25537
doi: 10.1002/mds.25537
pubmed: 23801585
Moura CS, Prado NM, Belo NO, Acurcio FA (2012) Evaluation of drug-drug interaction screening software combined with pharmacist intervention. Int J Clin Pharm 34:547–552. https://doi.org/10.1007/s11096-012-9642-2
doi: 10.1007/s11096-012-9642-2
pubmed: 22535491
Müller-Rebstein S, Trenkwalder C, Ebentheuer J et al (2017) Drug safety analysis in a real-life cohort of Parkinson’s disease patients with polypharmacy. CNS Drugs 31:1093–1102. https://doi.org/10.1007/s40263-017-0478-0
doi: 10.1007/s40263-017-0478-0
pubmed: 29139041
Nagayama H, Ueda M, Kumagai T et al (2011) Influence of ageing on the pharmacokinetics of levodopa in elderly patients with Parkinson’s disease. Parkinsonism Relat Disord 17:150–152. https://doi.org/10.1016/j.parkreldis.2010.11.002
doi: 10.1016/j.parkreldis.2010.11.002
pubmed: 21172738
Oertel W, Eggert K, Pahwa R et al (2017) Randomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson’s disease (EASE LID 3). Mov Disord 32:1701–1709. https://doi.org/10.1002/mds.27131
doi: 10.1002/mds.27131
pubmed: 28833562
pmcid: 5763269
Okunoye O, Kojima G, Marston L et al (2020) Factors associated with hospitalisation among people with Parkinson’s disease—A systematic review and meta-analysis. Parkinsonism Relat Disord 71:66–72. https://doi.org/10.1016/j.parkreldis.2020.02.018
doi: 10.1016/j.parkreldis.2020.02.018
pubmed: 32156461
Oscanoa TJ, Lizaraso F, Carvajal A (2017) Hospital admissions due to adverse drug reactions in the elderly. A meta-analysis. Eur J Clin Pharmacol 73:759–770. https://doi.org/10.1007/s00228-017-2225-3
doi: 10.1007/s00228-017-2225-3
pubmed: 28251277
Palmaro A, Dupouy J, Lapeyre-Mestre M (2015) Benzodiazepines and risk of death: results from two large cohort studies in France and UK. Eur Neuropsychopharmacol 25:1566–1577. https://doi.org/10.1016/j.euroneuro.2015.07.006
doi: 10.1016/j.euroneuro.2015.07.006
pubmed: 26256008
Panisset M, Chen JJ, Rhyee SH et al (2014) Serotonin toxicity association with concomitant antidepressants and rasagiline treatment: retrospective study (STACCATO). Pharmacotherapy 34:1250–1258. https://doi.org/10.1002/phar.1500
doi: 10.1002/phar.1500
pubmed: 25314256
Pasina L, Djade CD, Nobili A et al (2013) Drug-drug interactions in a cohort of hospitalized elderly patients. Pharmacoepidemiol Drug Saf 22:1054–1060. https://doi.org/10.1002/pds.3510
doi: 10.1002/pds.3510
pubmed: 24038765
Pazan F, Weiss C, Wehling M, FORTA (2018) The EURO-FORTA (Fit fOR The Aged) list: international consensus validation of a clinical tool for improved drug treatment in older people. Drugs Aging 35:61–71. https://doi.org/10.1007/s40266-017-0514-2
doi: 10.1007/s40266-017-0514-2
pubmed: 29335932
Pazan F, Weiss C, Wehling M, FORTA (2019) The FORTA (Fit fOR The Aged) list 2018: third version of a validated clinical tool for improved drug treatment in older people. Drugs Aging 36:481–484. https://doi.org/10.1007/s40266-019-00669-6
doi: 10.1007/s40266-019-00669-6
pubmed: 30941728
Pazan F, Gercke Y, Weiss C et al (2020) The U.S.-FORTA (Fit fOR The Aged) list: consensus validation of a clinical tool to improve drug therapy in older adults. J Am Med Dir Assoc 21:439.e9-439.e13. https://doi.org/10.1016/j.jamda.2019.07.023
doi: 10.1016/j.jamda.2019.07.023
Peball M, Mahlknecht P, Werkmann M et al (2019) Prevalence and associated factors of sarcopenia and frailty in Parkinson’s disease: a cross-sectional study. Gerontology 65:216–228. https://doi.org/10.1159/000492572
doi: 10.1159/000492572
pubmed: 30199864
Roblek T, Vaupotic T, Mrhar A, Lainscak M (2015) Drug-drug interaction software in clinical practice: a systematic review. Eur J Clin Pharmacol 71:131–142. https://doi.org/10.1007/s00228-014-1786-7
doi: 10.1007/s00228-014-1786-7
pubmed: 25529225
Sánchez-Arenas R, Sánchez-García S, García-Peña C et al (2012) Drug-drug interactions at hospital admission in geriatric patients in a single facility: a retrospective study. Int J Clin Pharmacol Ther 50:426–430. https://doi.org/10.5414/CP201551
doi: 10.5414/CP201551
pubmed: 22541743
Santos-Eggimann B, Cuénoud P, Spagnoli J, Junod J (2009) Prevalence of frailty in middle-aged and older community-dwelling Europeans living in 10 countries. J Gerontol A Biol Sci Med Sci 64:675–681. https://doi.org/10.1093/gerona/glp012
doi: 10.1093/gerona/glp012
pubmed: 19276189
Savarese M, Carnicelli M, Cardinali V et al (2015) Subjective hypnotic efficacy of trazodone and mirtazapine in patients with chronic insomnia: a retrospective, comparative study. Arch Ital Biol 153:231–238. https://doi.org/10.12871/0003982920152348
doi: 10.12871/0003982920152348
pubmed: 26742677
Sawada H, Oeda T, Kuno S et al (2010) Amantadine for dyskinesias in Parkinson’s disease: a randomized controlled trial. PLoS ONE 5:e15298. https://doi.org/10.1371/journal.pone.0015298
doi: 10.1371/journal.pone.0015298
pubmed: 21217832
pmcid: 3013111
Seitz DP, Gill SS, Conn DK (2010) Citalopram versus other antidepressants for late-life depression: a systematic review and meta-analysis. Int J Geriatr Psychiatry 25:1296–1305. https://doi.org/10.1002/gps.2483
doi: 10.1002/gps.2483
pubmed: 21086540
Seppi K, Ray Chaudhuri K, Coelho M et al (2019) Update on treatments for nonmotor symptoms of Parkinson’s disease-an evidence-based medicine review. Mov Disord 34:180–198. https://doi.org/10.1002/mds.27602
doi: 10.1002/mds.27602
pubmed: 30653247
pmcid: 6916382
Sieber CC (2007) The elderly patient–who is that? Internist (Berl) 48(1190):1192–1194. https://doi.org/10.1007/s00108-007-1945-3
doi: 10.1007/s00108-007-1945-3
Skorvanek M, Rosenberger J, Minar M et al (2015) Relationship between the non-motor items of the MDS-UPDRS and quality of life in patients with Parkinson’s disease. J Neurol Sci. https://doi.org/10.1016/j.jns.2015.04.013
doi: 10.1016/j.jns.2015.04.013
pubmed: 25918077
Smith KM, Eyal E, Weintraub D (2015) Combined rasagiline and antidepressant use in Parkinson disease in the ADAGIO Study: effects on nonmotor symptoms and tolerability. JAMA Neurol 72:88. https://doi.org/10.1001/jamaneurol.2014.2472
doi: 10.1001/jamaneurol.2014.2472
pubmed: 25420207
Stacy M, Silver D (2008) Apomorphine for the acute treatment of “off” episodes in Parkinson’s disease. Parkinsonism Relat Disord 14:85–92. https://doi.org/10.1016/j.parkreldis.2007.07.016
doi: 10.1016/j.parkreldis.2007.07.016
pubmed: 18083605
Stibe CM, Lees AJ, Kempster PA, Stern GM (1988) Subcutaneous apomorphine in parkinsonian on-off oscillations. Lancet 1:403–406. https://doi.org/10.1016/s0140-6736(88)91193-2
doi: 10.1016/s0140-6736(88)91193-2
pubmed: 2893200
The FORTA authors/expert panel members, Kuhn-Thiel AM, Weiß C, Wehling M (2014) Consensus validation of the FORTA (Fit fOR The Aged) list: a clinical tool for increasing the appropriateness of pharmacotherapy in the elderly. Drugs Aging 31:131–140. https://doi.org/10.1007/s40266-013-0146-0
doi: 10.1007/s40266-013-0146-0
Thevelin S, El ML, Marien S et al (2019) Potentially inappropriate prescribing and related hospital admissions in geriatric patients: a comparative analysis between the STOPP and START criteria versions 1 and 2. Drugs Aging. https://doi.org/10.1007/s40266-018-00635-8
doi: 10.1007/s40266-018-00635-8
pubmed: 30694444
Thorlund K, Druyts E, Wu P et al (2015) Comparative efficacy and safety of selective serotonin reuptake inhibitors and serotonin-norepinephrine reuptake inhibitors in older adults: a network meta-analysis. J Am Geriatr Soc 63:1002–1009. https://doi.org/10.1111/jgs.13395
doi: 10.1111/jgs.13395
pubmed: 25945410
Tolosa E, Hernández B, Linazasoro G et al (2014) Efficacy of levodopa/carbidopa/entacapone versus levodopa/carbidopa in patients with early Parkinson’s disease experiencing mild wearing-off: a randomised, double-blind trial. J Neural Transm (Vienna) 121:357–366. https://doi.org/10.1007/s00702-013-1114-x
doi: 10.1007/s00702-013-1114-x
Tönges L, Bartig D, Muhlack S et al (2019) Characteristics and dynamics of inpatient treatment of patients with Parkinson’s disease in Germany: analysis of 1.5 million patient cases from 2010 to 2015. Nervenarzt 90:167–174. https://doi.org/10.1007/s00115-018-0590-5
doi: 10.1007/s00115-018-0590-5
pubmed: 30083879
Truong DD (2009) Tolcapone: review of its pharmacology and use as adjunctive therapy in patients with Parkinson’s disease. Clin Interv Aging 4:109–113. https://doi.org/10.2147/cia.s3787
doi: 10.2147/cia.s3787
pubmed: 19503773
pmcid: 2685232
Valkovic P, Harsany J, Hanakova M et al (2014) Nonmotor symptoms in early- and advanced-stage Parkinson’s disease patients on dopaminergic therapy: how do they correlate with quality of life? ISRN Neurol. https://doi.org/10.1155/2014/587302
doi: 10.1155/2014/587302
pubmed: 24729891
pmcid: 3963114
Wehling M, Burkhardt H, Kuhn-Thiel A et al (2016) VALFORTA: a randomised trial to validate the FORTA (Fit fOR The Aged) classification. Age Ageing 45:262–267. https://doi.org/10.1093/ageing/afv200
doi: 10.1093/ageing/afv200
pubmed: 26786346
Xing D, Ma XL, Ma JX et al (2014) Association between use of benzodiazepines and risk of fractures: a meta-analysis. Osteoporos Int 25:105–120. https://doi.org/10.1007/s00198-013-2446-y
doi: 10.1007/s00198-013-2446-y
pubmed: 24013517
Zhong G, Wang Y, Zhang Y, Zhao Y (2015) Association between benzodiazepine use and dementia: a meta-analysis. PLoS ONE 10:e0127836. https://doi.org/10.1371/journal.pone.0127836
doi: 10.1371/journal.pone.0127836
pubmed: 26016483
pmcid: 26016483